Diagnosis, Management, and Associated Comorbidities of Polycystic Ovary Syndrome: A Narrative Review

被引:7
作者
Choudhari, Rutuja [1 ]
Tayade, Surekha [1 ]
Tiwari, Aakriti [1 ]
Satone, Prasiddhi [1 ]
机构
[1] Datta Meghe Inst Higher Educ & Res, Dept Obstet & Gynaecol, Wardha, India
关键词
anovulation; reproductive age group; endocrine disorder; infertility; hyperandrogenism; insulin resistance; polycystic ovary syndrome (pcos); IMPAIRED GLUCOSE-TOLERANCE; ANDROGEN EXCESS; INSULIN-RESISTANCE; WOMEN; RISK; PREVALENCE; CRITERIA; PATHOGENESIS; PREDICTORS; DEPRESSION;
D O I
10.7759/cureus.58733
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polycystic ovary syndrome (PCOS) is the most widespread and diverse endocrine health issue affecting many adolescent-aged women globally. It is the most frequent illness in reproductive-aged women. According to the Rotterdam criteria, two out of three elements: oligo-anovulation, hyperandrogenism, and polycystic ovaries (defined as having at least one ovary with an ovarian volume > 10 mL and/or 12 or more follicles measuring 2 to 9 mm in diameter) are present in PCOS. Conducted studies show epigenetics, environmental toxins, stress, and food as external factors as well as inflammation, oxidative stress, hyperandrogenism, insulin resistance, and obesity as internal factors related to PCOS. Although a portion of the mechanism associated with the occurrence of PCOS has been identified, there is still much to learn about the exact etiology and pathophysiology. The main debate covers the best ways to diagnose and treat this disease in adolescents. Early detection is crucial because of the disease's long-term effects on metabolic and reproductive health. Before beginning treatment for this group of young women, a firm diagnosis may not be made. Various criteria are used to diagnose PCOS patients. A person with PCOS has a chance of developing several comorbidities and health effects. PCOS patients are at risk of cardiac diseases, metabolic syndromes, resistance to insulin, infertility, and many more. There are numerous medications available for PCOS therapy that need a methodical approach. However, changing one's lifestyle should come first. There is proof in the support of the usage of several medications for PCOS, including mucolytic agents, Hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors, gliptins (oral diabetic medication), glucoselike peptide-1 receptor analogues, glitazones, and sodium-glucose cotransporter protein-2 (SGLT2) inhibitors. A comprehensive, systematic, schematic therapy approach is crucial for the treatment of PCOS.
引用
收藏
页数:10
相关论文
共 55 条
  • [1] American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee, 2005, Endocr Pract, V11, P126
  • [2] Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome
    Apparao, KBC
    Lovely, LP
    Gui, YT
    Lininger, RA
    Lessey, BA
    [J]. BIOLOGY OF REPRODUCTION, 2002, 66 (02) : 297 - 304
  • [3] Androgenetic alopecia and cardiovascular risk factors in men and women: A comparative study
    Arias-Santiago, Salvador
    Teresa Gutierrez-Salmeron, Maria
    Castellote-Caballero, Luisa
    Buendia-Eisman, Agustin
    Naranjo-Sintes, Ramon
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (03) : 420 - 429
  • [4] Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline
    Azziz, Ricardo
    Carmina, Enrico
    Dewailly, Didier
    Diamanti-Kandarakis, Evanthia
    Escobar-Morreale, Hector F.
    Futterweit, Walter
    Janssen, Onno E.
    Legro, Richard S.
    Norman, Robert J.
    Taylor, Ann E.
    Witchel, Selma F.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11) : 4237 - 4245
  • [5] The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report
    Azziz, Ricardo
    Carmina, Enrico
    Dewailly, Didier
    Diamanti-Kandarakis, Evanthia
    Escobar-Morreale, Hector F.
    Futterweit, Walter
    Janssen, Onno E.
    Legro, Richard S.
    Norman, Robert J.
    Taylor, Ann E.
    Witchel, Selina F.
    [J]. FERTILITY AND STERILITY, 2009, 91 (02) : 456 - 488
  • [6] POLYCYSTIC-OVARY-SYNDROME - THE SPECTRUM OF THE DISORDER IN 1741 PATIENTS
    BALEN, AH
    CONWAY, GS
    KALTSAS, G
    TECHATRAISAK, K
    MANNING, PJ
    WEST, C
    JACOBS, HS
    [J]. HUMAN REPRODUCTION, 1995, 10 (08) : 2107 - 2111
  • [7] The pathogenesis and treatment of polycystic ovary syndrome: What's new?
    Bednarska, Sylwia
    Siejka, Agnieszka
    [J]. ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 26 (02): : 359 - 367
  • [8] Bolúmar F, 2000, AM J EPIDEMIOL, V151, P1072, DOI 10.1093/oxfordjournals.aje.a010150
  • [9] Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism
    Carmina, E
    Rosato, F
    Jannì, A
    Rizzo, M
    Longo, RA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) : 2 - 6
  • [10] Cunha Anita, 2021, Porto Biomed J, V6, pe116, DOI 10.1097/j.pbj.0000000000000116